Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Current Deferred Revenue came in at $5.0 million in Q1 2026, up 9.62% YoY from $4.6 million in Q1 2025, and up 35.38% on a QoQ basis from $3.7 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 10 years of Current Deferred Revenue data on file, last reported at $5.0 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 9.62% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 9.62% YoY) and the FY2025 annual result came in at $3.7 million, down 66.19% from the prior year.
- Current Deferred Revenue improved to $5.0 million in Q1 2026, from $3.7 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $11.0 million in Q4 2024 to a low of $3.1 million in Q4 2022.
- A 5-year average of $4.8 million and a median of $4.6 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 1556.84% — and 2025, when it sank 66.19%.
- Tracing AUPH's Current Deferred Revenue over 5 years: stood at $3.1 million in 2022, then soared by 52.89% to $4.8 million in 2023, then jumped by 128.59% to $11.0 million in 2024, then slumped by 66.19% to $3.7 million in 2025, then soared by 35.38% to $5.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $5.0 million (Q1 2026), $3.7 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.59 Mn |
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 4.59 Mn |
| Dec 31, 2024 | 11.00 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 4.81 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Dec 31, 2021 | 190,000.00 |
| Dec 31, 2019 | 118,000.00 |
| Dec 31, 2018 | 118,000.00 |
| Dec 31, 2017 | 118,000.00 |
| Dec 31, 2016 | 118,000.00 |